• Hero Banner
  • ACVCACVC
  • DVM 360
  • Fetch DVM 360Fetch DVM 360
DVM 360
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
By Role
AssociatesOwnersPractice ManagerStudentsTechnicians
Subscriptions
dvm360 Newsletterdvm360 Magazine
News
All News
Association
Breaking News
Education
Equine
FDA
Law & Ethics
Market Trends
Medical
Products
Recalls
Regulatory
Digital Media
dvm360 LIVE!™
Expert Interviews
The Vet Blast Podcast
Medical World News
Pet Connections
The Dilemma Live
Vet Perspectives™
Weekly Newscast
dvm360 Insights™
Publications
All Publications
dvm360
Firstline
Supplements
Top Recommended Veterinary Products
Vetted
Clinical
All Clinical
Anesthesia
Animal Welfare
Behavior
Cardiology
CBD in Pets
Dentistry
Dermatology
Diabetes
Emergency & Critical Care
Endocrinology
Equine Medicine
Exotic Animal Medicine
Feline Medicine
Gastroenterology
Imaging
Infectious Diseases
Integrative Medicine
Nutrition
Oncology
Ophthalmology
Orthopedics
Pain Management
Parasitology
Pharmacy
Surgery
Toxicology
Urology & Nephrology
Virtual Care
Business
All Business
Business & Personal Finance
Buying or Selling a Practice
Hospital Design
Leadership & Personal Growth
Personnel Management
Practice Finances
Practice Operations
Technology
Wellbeing & Lifestyle
Continuing Education
Conferences
Live Conferences
Conference News
Conference Proceedings
Resources
CBD in Pets
Contests
Veterinary Heroes
Partners
Spotlight Series
Team Meeting in a Box
Toolkit
Top Recommended Veterinary Products
Vet to Vet
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us

© 2023 MJH Life Sciences and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Advertisement
By Role
  • Associates
  • Owners
  • Practice Manager
  • Students
  • Technicians
Subscriptions
  • dvm360 Newsletter
  • dvm360 Magazine
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us
  • MJHLS Brand Logo

© 2023 MJH Life Sciences™ and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

USDA grants license approval for Circumvent CML vaccine for pigs

June 8, 2022
dvm360 Staff

Merck claims the vaccine is effective against disease caused by Porcine Circovirus Types 2a and 2d, Mycoplasma hyopneumoniae and Lawsonia intracellularis in pigs, 3 weeks of age and older

Merck Animal Health announced today that it has received license approval in the US from the Department of Agriculture (USDA) for its Circumvent CML vaccine. Merck issued a press release that claims Circumvent CML is the first-ready-to-use, single-dose vaccine effective against disease caused by Porcine Circovirus Types 2a and 2d, Mycoplasma hyopneumoniae, and Lawsonia intracellularis in pigs, 3 weeks of age or older.1

The Circumvent CML product label provided by Merck additionally claims that the duration of immunity for Porcine Circovirus Type 2d is at least 16 weeks, the duration for immunity for Mycoplasma hyopneumoniae is at least 10 weeks, and the Duration of immunity for ileitis due to Lawsonia intracellularis is at least 20 weeks. However, the duration of immunity for Porcine Circovirus Type 2a has not been established.2

“Merck Animal Health is excited to bring this important innovation to our customers as part of our commitment to offering comprehensive solutions for improved animal health outcomes,” said Jamie Lehman, DVM, swine technical services veterinarian at Merck Animal Health.

Advertisement

“This vaccine nicely complements Circumvent PCV G2, PCV-M G2, and Porcilis Ileitis product portfolio, providing swine veterinarians and producers the additional option of vaccinating against disease caused by PCV2, Mycoplasma hyopneumoniae, and Lawsonia intracellularis all in 1 bottle.”

Merck says Circumvent CML will be available in 50-ml, 250-ml, and eventually, 500-ml dose presentations, beginning in early 2023.

References

  1. Merck Animal Health Receives License Approval for CIRCUMVENT® CML Vaccine. News release. June 8, 2022. Accessed June 8, 2022. https://www.merck-animal-health-usa.com/uncategorized/merck-animal-health-receives-license-approval-for-circumvent-cml-vaccine
  2. Circumvent® C-M-L (MERCK ANIMAL HEALTH). DVM Metrics and Services, LLC. Accessed June 8, 2022. https://merckusa.cvpservice.com/product/basic/view/1047582?key=label

Related Content:

MedicalFood Animals
Integrative approach to treating Giardia lamblia infections
Integrative approach to treating Giardia lamblia infections
Innovative digital microscopy platform is launched
Innovative digital microscopy platform is launched
Drug for acute onset of canine pancreatitis is launched on the US market
Drug for acute onset of canine pancreatitis is launched on the US market

Advertisement

Latest News

Oldest aardvark in Europe passes away

Integrative approach to treating Giardia lamblia infections

Innovative digital microscopy platform is launched

Enhanced pet health and wellness app now available

View More Latest News
Advertisement